These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24707945)

  • 1. Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant.
    Radujkovic A; Hundemer M; Eisenbach C; Luft T; Penzel R; Goldschmidt H; Ho AD; Bellos F
    Leuk Lymphoma; 2014 Dec; 55(12):2967-9. PubMed ID: 24707945
    [No Abstract]   [Full Text] [Related]  

  • 2. Engraftment syndrome after hematopoietic stem cell transplantation in multiple myeloma.
    Katzel JA; Mazumder A; Jagannath S; Vesole DH
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):151. PubMed ID: 17026829
    [No Abstract]   [Full Text] [Related]  

  • 3. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
    Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
    J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of melphalan in myeloma patients undergoing an autograft.
    Nath CE; Shaw PJ; Trotman J; Zeng L
    Bone Marrow Transplant; 2007 Oct; 40(7):707-8. PubMed ID: 17680022
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later.
    Lazarus HM; Phillips GL; Herzig RH; Hurd DD; Wolff SN; Herzig GP
    J Clin Oncol; 2008 May; 26(14):2240-3. PubMed ID: 18467711
    [No Abstract]   [Full Text] [Related]  

  • 7. Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.
    Beaven AW; Moore DT; Sharf A; Serody JS; Shea TC; Gabriel DA
    Cancer Invest; 2011 Mar; 29(3):214-9. PubMed ID: 21314330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
    Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment.
    Clemmons AB; Anderegg S
    J Oncol Pharm Pract; 2017 Jul; 23(5):384-388. PubMed ID: 27000280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
    Labidi SI; Sebban C; Ghesquières H; Nicolas EV; Biron P
    Int J Hematol; 2008 Oct; 88(3):291-293. PubMed ID: 18696182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
    Martino M; Praticò G; Messina G; Irrera G; Massara E; Messina G; Console G; Iacopino P
    Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
    Chen J; Seabrook J; Fulford A; Rajakumar I
    J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
    Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD; Lechowicz MJ; Khoury HJ; Flowers CR; Waller EK
    Clin Cancer Res; 2010 Oct; 16(20):5079-86. PubMed ID: 20739431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma.
    Talamo G; Rakszawski KL; Rybka WB; Dolloff NG; Malysz J; Berno T; Zangari M
    Eur J Haematol; 2012 Aug; 89(2):145-50. PubMed ID: 22540279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.
    Shah N; Thall PF; Fox PS; Bashir Q; Shah JJ; Parmar S; Lin P; Kebriaei P; Nieto Y; Popat UR; Hosing CM; Cornelison A; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Leukemia; 2015 Sep; 29(9):1945-8. PubMed ID: 25721897
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation.
    Nishihori T; Hassoun Y; Zhang L; Shain K; Alsina M; Kharfan-Dabaja MA
    Bone Marrow Transplant; 2014 Jan; 49(1):148-9. PubMed ID: 23933759
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.